Devyser secures a major SEK 16.8M tender in Italy with 30% growth
Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for...
At present, FH is greatly underdiagnosed, and most cases are not discovered until the affected individual suffers his or her first cardiovascular event.
This paper by Peter Benedek and Kristina Duvefelt, Karolinska University Hospital, Stockholm, Sweden, introduces the clinical diagnosis, indicators and symptoms, and treatment of FH, before examining the background and current status of genetic testing for FH, and new best practices enabled by Next Generation Sequencing.
At present, FH is greatly underdiagnosed, and most cases are not discovered until the affected individual suffers his or her first cardiovascular event.
This paper by Peter Benedek and Kristina Duvefelt, Karolinska University Hospital, Stockholm, Sweden, introduces the clinical diagnosis, indicators and symptoms, and treatment of FH, before examining the background and current status of genetic testing for FH, and new best practices enabled by Next Generation Sequencing.
Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for...
Read More
Devyser has launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution designed...
Read More
Thalassemia and hemoglobinopathies are among the most common genetic disorders worldwide, affecting...
Read More
Read More